This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Findings from the highly-anticipated MOST (Multi-Arm Optimization of StrokeThrombolysis) trial were presented on the first day of the American Stroke Association’s International Stroke Conference, ISC 2024, being held through Feb. A lot of our approaches in stroke treatment were learned from how we treat heart attacks.
Stroke, Volume 55, Issue Suppl_1 , Page AWP20-AWP20, February 1, 2024. Importance:Tenecteplase use is more prevalent as the thrombolytic drug of choice for acute ischemic stroke, with results demonstrating its non-inferiority compared to alteplase. Results:Median age was 62.94 for alteplase and 64.45
Stroke, Volume 56, Issue Suppl_1 , Page ADP4-ADP4, February 1, 2025. Introduction:Intravenous thrombolysis with alteplase (tPA) or tenecteplase (TNK) is a first-line treatment for acute ischemic stroke. The most serious risk associated with IV thrombolytics is symptomatic intracranial hemorrhage (sICH).
Stroke, Volume 56, Issue Suppl_1 , Page ATP8-ATP8, February 1, 2025. Introduction:Treatment of acute stroke has its clear rules and established standards. The neurological deficit corresponded to 5 points in the median NIHSS after a previous stroke, 11 points at the time of recurrence, and 7 points after rescue therapy.
Stroke, Ahead of Print. BACKGROUND:Timely intravenous thrombolysis and endovascular thrombectomy are the standard reperfusion treatments for large vessel occlusion stroke. 0.98]), a numerically higher incidence of symptomatic intracerebral hemorrhage (6.7% mg/kg alteplase).METHODS:We mg/kg alteplase).METHODS:We
Stroke, Volume 56, Issue Suppl_1 , Page AWP11-AWP11, February 1, 2025. Introduction:Stroke is a leading cause of disability and mortality worldwide, with thrombolysis as a critical treatment. Studies aiming to assess the outcomes of thrombolysis after ischemic stroke in LMIC were selected.
Stroke, Volume 56, Issue Suppl_1 , Page ADP3-ADP3, February 1, 2025. Background:Current guidelines for ischemic stroke recommend initiating intravenous thrombolytic therapy within 4.5 hours after stroke onset or the last known well time. These modalities can identify viable brain tissue beyond the 4.5-hour h to standard of care.
Stroke, Volume 56, Issue Suppl_1 , Page ADP1-ADP1, February 1, 2025. Background:Cerebral amyloid angiopathy (CAA) is a hemorrhagic cerebrovascular disease that is thought to be due to excess protein deposition in vessel walls that lead to fragility and increase the risk of rupture. to 5.75], p<0.001), and SAH (aOR 2.42 [95%CI 1.41-4.16],
Stroke, Volume 55, Issue Suppl_1 , Page A59-A59, February 1, 2024. Introduction:Many patients are taking antiplatelet medications when an acute stroke occurs. The exposure of interest was pre-stroke antiplatelet use categorized as none, single (SAPT), and dual antiplatelet therapy (DAPT). no antiplatelet, 36.7% SAPT, and 6.4%
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionImportance:Tenecteplase (TNK) use is more prevalent as the thrombolytic drug of choice for acute ischemic stroke (AIS), given its ease of use with results from randomized trials showing non‐ inferiority and comparable safety to Alteplase (tPA).
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionIntravenous thrombolytics (IVT) and mechanical thrombectomy (MT) have become the standards of care for treating patients with large vessel occlusion (LVO) acute ischemic strokes (AIS) [1‐4}. in a large multicentered meta‐analysis [2,6].
Stroke, Volume 56, Issue Suppl_1 , Page A4-A4, February 1, 2025. Introduction:The tenecteplase versus standard of care for minor ischemic stroke with proven occlusion (TEMPO-2) trial showed that patients presenting with minor deficits up to 12 h do not benefit from intravenous thrombolysis. vs control 2.1%, P=0.005.
Stroke, Volume 56, Issue Suppl_1 , Page AWP1-AWP1, February 1, 2025. Background and aims:Central retinal artery occlusion (CRAO) is a rare but significantly underestimated form of ischemic stroke. One of the considered and currently increasingly preferred options is intravenous thrombolysis. years, 46.9%
Stroke, Volume 56, Issue Suppl_1 , Page AWP9-AWP9, February 1, 2025. Background:Acute ischemic stroke can result from extracranial arterial dissection. The effectiveness and safety of intravenous thrombolysis (IVT) for acute ischemic stroke in these cases, particularly those involving large vessel occlusions, are debated.
Stroke, Volume 56, Issue Suppl_1 , Page ATP20-ATP20, February 1, 2025. The primary outcome was 3-month functional outcome by modified Rankin scale (mRS). Patients with elevated traditional risk factors at admission may benefit more from thrombolytic therapy compared to those with high inflammatory response indicators.
Stroke, Volume 55, Issue Suppl_1 , Page AWMP78-AWMP78, February 1, 2024. Introduction:Mobile stroke units (MSUs) are an evolving means to expedited acute stroke management. The target blood pressure goal was met much quicker in the MSU. Faster time metrics convey a hypothetical benefit towards improved patient outcomes.
Stroke, Volume 56, Issue Suppl_1 , Page AWP253-AWP253, February 1, 2025. Background and Aims:Endovascular treatment (EVT) alone has been confirmed to be non-inferior to intravenous thrombolysis (IVT) followed with EVT in acute ischemic stroke (AIS) due to large-vessel occlusion of the anterior circulation.
Stroke, Volume 56, Issue Suppl_1 , Page ATP11-ATP11, February 1, 2025. Introduction:Current guidelines suggest using intravenous thrombolysis (IVT) for patients experiencing acute ischemic stroke within 4.5 The safety outcome was the rate of symptomatic intracranial hemorrhage (SICH).Results:We hours of symptom onset.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP72-AWMP72, February 1, 2025. Introduction:Emerging technologies, such as Cone-Beam CT (CBCT), may improve workflows in acute ischemic stroke (AIS). Conclusion:CBCT had high specificity for ICH and hemorrhage types.
Stroke, Ahead of Print. BACKGROUND:The effectiveness of intravenous thrombolysis (IVT) before endovascular treatment (EVT) has been investigated in randomized trials and meta-analyses. Although symptomatic intracranial hemorrhages occurred more often in the IVT group (4.8%
Stroke, Volume 56, Issue Suppl_1 , Page ATP19-ATP19, February 1, 2025. Background:Patients with acute ischemic stroke and a large vessel occlusion (LVO) admitted to primary stroke centers (PSC) often require inter-facility transfer for thrombectomy.
Stroke, Volume 56, Issue Suppl_1 , Page A30-A30, February 1, 2025. Background and objective:Perfusion imaging studies consistently show a substantially increased risk of hemorrhagic transformation (HT) in severely hypoperfused tissue.
Stroke, Volume 56, Issue Suppl_1 , Page ATP9-ATP9, February 1, 2025. Introduction:Tenecteplase (TNK) is now an accepted alternative to Alteplase (ALT) for intravenous thrombolysis (IVT) in acute ischemic stroke (AIS). Time to IVT was grouped as ultra-early (0-90 min), early (91-180 min), and late (181-270 min).
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionEfficacy and safety of intravenous thrombolysis (IVT) in patients undergoing mechanical thrombectomy (MT) is still debatable. ResultsWe included four randomized controlled trials with 1176 patients.
Stroke, Volume 56, Issue Suppl_1 , Page ATP242-ATP242, February 1, 2025. Background:Symptomatic intracranial hemorrhage (sICH) is the most dreaded complication after reperfusion therapy for acute ischemic stroke. 2.07; P = 0.037). 2.07; P = 0.037). Risk of sICH was comparable between the MT and MT+IVT groups (RR: 0.77; 95%CI: 0.57-1.03;
Stroke, Volume 56, Issue Suppl_1 , Page AWP245-AWP245, February 1, 2025. Background and Aims:Previous studies indicated the usual dose heparin(5000 IU bolus followed by 500~1250 IU/h) during mechanical thrombectomy(MT) is associated with an increased risk of hemorrhagic conversion without beneficial effect. vs 21.3%, p=0.04).
Stroke, Volume 55, Issue Suppl_1 , Page AWP177-AWP177, February 1, 2024. Definitions of symptomatic HT developed during the intravenous thrombolysis (IVT) era are outdated in the endovascular thrombectomy (EVT) era but continue to be widely used. Background:Hemorrhagic transformation (HT) is the principal adverse event of thrombectomy.
Stroke, Volume 56, Issue Suppl_1 , Page ATP190-ATP190, February 1, 2025. Background:The prognostic significance of the affected hemisphere in hemorrhagicstroke remains uncertain. The association of ICH laterality with clinical outcomes was estimated using multiple linear regression models.
Stroke, Volume 55, Issue Suppl_1 , Page AWP202-AWP202, February 1, 2024. Background:Mechanical thrombectomy (MT) has demonstrated superiority over medical therapy for acute ischemic stroke (AIS) with large vessel occlusion (LVO).
Stroke, Volume 55, Issue Suppl_1 , Page ATMP63-ATMP63, February 1, 2024. Background:The American Heart Association guidelines recommend BP goal of <180/105 mmHg for the first 24 hours in acute ischemic stroke (AIS) patients treated with IV Alteplase and now adopted for IV Tenecteplase (TNK). vs 4.9%; p=0.3) vs 1.4%; p=0.2).Conclusion:Our
Stroke, Volume 56, Issue Suppl_1 , Page AWP225-AWP225, February 1, 2025. Background:Intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are the standard of care for select stroke patients with acute large vessel occlusion (LVO).
Stroke, Volume 55, Issue Suppl_1 , Page AWP154-AWP154, February 1, 2024. Prolonged ICU stay were more likely to have higher baseline median NIHSS score (19 vs. 14%, p < 0.0001), posterior circulation stroke (12.6% vs. 6.1%, p = 0.0326), and symptomatic intracerebral hemorrhage (7.3% vs. 1.9%, p = 0.0109). p = 0.0157).Conclusions:Almost
Stroke, Volume 55, Issue Suppl_1 , Page AWP179-AWP179, February 1, 2024. Background:Stent-retriever thrombectomy is the first-line therapy for acute stroke with intracranial large vessel occlusion. In cases of stent-retriever thrombectomy failure, rescue stent angioplasty might be the sole option for achieving permanent recanalization.
Stroke, Volume 56, Issue Suppl_1 , Page AWP72-AWP72, February 1, 2025. Background:Our system, comprised of 21 Northeast Ohio hospitals includes 3 Stroke Ready, 10 Primary and 1 Comprehensive Stroke Center (CSC). Clinical trials support the efficacy and safety of Tenecteplase for the treatment of acute ischemic stroke (AIS).
Stroke, Volume 56, Issue 1 , Page 183-189, January 1, 2025. BACKGROUND:Thrombectomy for acute large vessel occlusion is a well-established treatment for stroke prevention. Infarct expansion, defined as a decrease in Alberta Stroke Program Early CT Score, occurred in 23 cases (12/28 TICI 2b and 11/37 TICI 2c/3).
Stroke, Volume 55, Issue Suppl_1 , Page ATP146-ATP146, February 1, 2024. Introduction:Collateral status imaging parameters are associated with predicting hemorrhagic transformation (HT) in acute ischemic stroke caused by large vessel occlusions. p=0.006); CBV index (aOR 0.0002, 95% CI 0-0.1,
Stroke, Volume 55, Issue 1 , Page 78-88, January 1, 2024. BACKGROUND:The association of COVID-19 with higher bleeding risk and worse outcomes in acute ischemic stroke (AIS) undergoing revascularization may be related to the presence of infection symptoms. 1.99]; aOR, 1.63 [95% CI, 1.14–2.32], 2.32], respectively).
Stroke, Volume 55, Issue Suppl_1 , Page ATMP86-ATMP86, February 1, 2024. Introduction:Tenecteplase improves reperfusion and functional outcomes in stroke patients with large vessel occlusion. Primary safety outcome was parenchymal hematoma type 2 (PH2) intracerebral hemorrhage. Mean age was 68, and 50.0% were females.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
75 
Let's personalize your content